PUBLIC COMPANY
saveTARSUS
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retiresLilly will unite its U.S. and international commercial units as a long-time exec retires. Enanta's CEO will hang up his hat after 23 year at the helm. Estrella has tapped a new a CEO to lead it thr…fiercebiotech · 2d ago
- M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buyAfter a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a BioSpace analysis.biospace · 1mo ago
- Growth mode: 3 biotechs that are staffing up after series B raisesBiotechs that announced series B financing this year and are expanding their workforces include one that raised $2.1 billion and has partnerships with Eli Lilly, Johnson & Johnson and Novartis.biospace · 1mo ago
- Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialAfter former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…fiercebiotech · 1mo ago
- Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800MAlkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.”biopharma_dive · 2mo ago
- Tarsus bets $450M on Alkeus’ Stargardt drugTo broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies said Thursday morning. It's the l…endpoints · 2mo ago
- Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drugTarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.fiercebiotech · 2mo ago
- ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadershipThe ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.biopharma_dive · 3mo ago
- Ipsen succeeds in migraine trials; Tarsus buys iRenix for $75M upfrontPlus news on Alchemab, Scipher and Forte. 💉 Ipsen’s Dysport aces Phase 3 migraine trials: The biotech’s injectable neurotoxin met the primary endpoint of reducing monthly migraine days in two ...endpoints · 3mo ago
comments(0)
5-min edit window · permanent after that